Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma: A Phase I/II Study (PSHCI 10-011)

Trial Profile

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma: A Phase I/II Study (PSHCI 10-011)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cladribine (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Aug 2017 Study phase changed from phase I/II to only phase I.
    • 04 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2020.
    • 04 Aug 2017 Planned primary completion date changed to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top